Unusual Complication After Left-Lobe Liver Biopsy for Diffuse Liver Disease: Severe Bleeding From the Superior Epigastric Artery

2011 ◽  
Vol 197 (6) ◽  
pp. W1135-W1139 ◽  
Author(s):  
Gopal Vijayaraghavan ◽  
David Sheehan ◽  
Larry Zheng ◽  
Sarwat Hussain ◽  
Joseph Ferrucci
Keyword(s):  
Liver Disease ◽  
Liver Biopsy ◽  
Left Lobe ◽  
Unusual Complication ◽  
Severe Bleeding ◽  
Diffuse Liver Disease ◽  
Epigastric Artery

scholarly journals Ultrasound-based liver elastography: current results and future perspectives

2020 ◽  
Vol 45 (11) ◽  
pp. 3463-3472
Author(s):  
Cheng Fang ◽  
Paul S. Sidhu
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Liver Biopsy ◽  
Chronic Liver Disease ◽  
Research Direction ◽  
Chronic Liver ◽  
Current Evidence ◽  
Diffuse Liver Disease ◽  
Disease Spectrum ◽  
Liver Elastography

Abstract Chronic liver disease affects 185 million population worldwide. It encompasses a heterogenous disease spectrum, but all can lead to the development of liver fibrosis. The degree of liver fibrosis is not only a prognosticator, but has also been used to guide the treatment strategy and to evaluate treatment response. Traditionally, staging of liver fibrosis is determined on histological analysis using samples obtained from an invasive liver biopsy. Ultrasound-based liver elastography is a non-invasive method of assessing diffuse liver disease in patients with known chronic liver disease. The use of liver elastography has led to a significant reduction in the number of liver biopsies performed to assess the severity of liver fibrosis and a liver biopsy is now reserved for only select sub-groups of patients. The aim of this review article is to discuss the key findings and current evidence for ultrasound-based elastography in diffuse liver disease as well as the technical challenges and to evaluate the potential research direction.

Transjugular liver biopsy in patients with diffuse liver disease: comparison of three cores with one or two cores for accurate histological interpretation

2007 ◽  
Vol 27 (5) ◽  
pp. 646-653 ◽  
Author(s):  
E. Cholongitas ◽  
A. Quaglia ◽  
D. Samonakis ◽  
M. Mela ◽  
D. Patch ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Biopsy ◽  
Diffuse Liver Disease ◽  
Transjugular Liver Biopsy

Single-Pass Percutaneous Liver Biopsy for Diffuse Liver Disease Using an Automated Device: Experience in 154 Procedures

2005 ◽  
Vol 28 (5) ◽  
pp. 584-588 ◽  
Author(s):  
Gerant Rivera-Sanfeliz ◽  
Thomas B. Kinney ◽  
Steven C. Rose ◽  
Ayad K.M. Agha ◽  
Karim Valji ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Biopsy ◽  
Percutaneous Liver Biopsy ◽  
Diffuse Liver Disease ◽  
Single Pass

Study of Biochemical and Clinical Markers in Steatohepatitis Related to Obesity

2018 ◽  
Vol 69 (6) ◽  
pp. 1501-1505
Author(s):  
Roxana Maria Livadariu ◽  
Radu Danila ◽  
Lidia Ionescu ◽  
Delia Ciobanu ◽  
Daniel Timofte
Keyword(s):  
Liver Disease ◽  
Liver Biopsy ◽  
Large Scale ◽  
Biological Data ◽  
Obese Patients ◽  
Clinical Markers ◽  
Mean Values ◽  
Nonalcoholic Fatty Liver ◽  
Obstructive Sleep ◽  
Increased Risk

Nonalcoholic fatty liver disease (NAFLD) is highly associated to obesity and comprises several liver diseases, from simple steatosis to steatohepatitis (NASH) with increased risk of developing progressive liver fibrosis, cirrhosis and hepatocellular carcinoma. Liver biopsy is the gold standard in diagnosing the disease, but it cannot be used in a large scale. The aim of the study was the assessment of some non-invasive clinical and biological markers in relation to the progressive forms of NAFLD. We performed a prospective study on 64 obese patients successively hospitalised for bariatric surgery in our Surgical Unit. Patients with history of alcohol consumption, chronic hepatitis B or C, other chronic liver disease or patients undergoing hepatotoxic drug use were excluded. All patients underwent liver biopsy during sleeve gastrectomy. NAFLD was present in 100% of the patients: hepatic steatosis (38%), NASH with the two forms: with fibrosis (31%) and without fibrosis (20%), cumulating 51%; 7 patients had NASH with vanished steatosis. NASH with fibrosis statistically correlated with metabolic syndrome (p = 0.036), DM II (p = 0.01) and obstructive sleep apnea (p = 0.02). Waist circumference was significantly higher in the steatohepatitis groups (both with and without fibrosis), each 10 cm increase increasing the risk of steatohepatitis (p = 0.007). The mean values of serum fibrinogen and CRP were significantly higher in patients having the progressive forms of NAFLD. Simple clinical and biological data available to the practitioner in medicine can be used to identify obese patients at high risk of NASH, aiming to direct them to specialized medical centers.

The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease

2020 ◽  
Vol 26 (32) ◽  
pp. 3928-3938
Author(s):  
Grazia Pennisi ◽  
Ciro Celsa ◽  
Antonina Giammanco ◽  
Federica Spatola ◽  
Salvatore Petta
Keyword(s):  
Liver Disease ◽  
Liver Biopsy ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Assessment Tools ◽  
Hepatic Decompensation ◽  
Alcoholic Fatty Liver ◽  
Simple Steatosis ◽  
Life Threatening ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver diseases worldwide, involving about 25% of people. NAFLD incorporates a large spectrum of pathological conditions, from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis and its complications include hepatic decompensation and hepatocellular carcinoma (HCC). This progression occurs, over many years, in an asymptomatic way, until advanced fibrosis appears. Thus, the differentiation of NASH from simple steatosis and identification of advanced hepatic fibrosis are key issues. To date, the histological assessment of fibrosis with liver biopsy is the gold standard, but obviously, invasiveness is the greater threshold. In addition, rare but potentially life-threatening complications, poor acceptability, sampling variability and cost maybe restrict its use. Furthermore, due to the epidemic of NAFLD worldwide and several limitations of liver biopsy evaluation, noninvasive assessment tools to detect fibrosis in NAFLD patients are needed.

TYPE III PRO-COLLAGEN PEPTIDE IN LIVER DISEASE IN HAEMOPHILIA

1987 ◽  
Author(s):  
R S Evely ◽  
F E Preston ◽  
D R Triger ◽  
C R M Hay ◽  
M C Greves ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Biopsy ◽  
Statistical Significance ◽  
Type Iii ◽  
Amino Terminal ◽  
Collagen Peptide ◽  
Collagen Iii ◽  
Liver Biopsies ◽  
Progressive Liver Disease ◽  
Valuable Predictor

During the past 10 years we have carried out liver biopsies on haemophiliacs with biochemical evidence of chronic liver disease (CLD). To date 44 biopsies have been obtained from 35 patients. Histological diagnoses are Chronic Persistent Hepatitis (CPH) 24, Chronic Aggressive Hepatitis (CAH) 11 and Cirrhosis 9. Serial biopsies indicate that progressive liver disease is now a serious problem in haemophilia. Liver biopsy is not without risk and therefore it is important to identify factors which may be of value in predicting the nature of the liver disease or its progression. Since intra-hepatic fibrosis is a feature of CLD we measured Type III amino terminal propeptide of pro-collagen (PC III) by radio-immunoassay on samples taken within a mean of 4.8 months of the liver biopsy. A normal range was established as 4.3 - 15.7ng/ml on healthy subjects (median 7.0). Median values and ranges for patients with CPH (N=13), CAH (N=5) and cirrhosis (N=5) were 8 (5.4 - 23.4), 14.2 (7.2 - 19.8) and 14.2 (11.2 - 23.0)ng/ml respectively. Although pro-collagen III values tended to be higher in progressive liver disease (CAH and cirrhosis) this did not reach statistical significance. It would, therefore, appear that unlike serum IgG, pro-collagen III will not be a valuable predictor of progressive liver disease in haemophilia. A larger study is necessary to clarify this.

Focal and diffuse liver disease studied by quantitative microstructural sonography.

Radiology ◽  
1985 ◽  
Vol 155 (2) ◽  
pp. 457-462 ◽  
Author(s):  
D L King ◽  
F L Lizzi ◽  
E J Feleppa ◽  
P M Wai ◽  
M M Yaremko ◽  
...  
Keyword(s):  
Liver Disease ◽  
Diffuse Liver Disease

scholarly journals Ultrasound Examination in Diffuse Liver Disease

1987 ◽  
Vol 28 (3) ◽  
pp. 281-284 ◽  
Author(s):  
Lillemor Forsberg ◽  
C. H. Florén ◽  
E. Hederström ◽  
H. Prytz
Keyword(s):  
Liver Disease ◽  
Ultrasound Examination ◽  
Diffuse Liver Disease
Sign in / Sign up

Export Citation Format

Share Document